Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Elanco Tiergesundheit AG currently faces 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, ensuring that no single examiner is handling more than 1 matter for the company at this time. This distribution is mirrored by the presence of 4 distinct art units, which indicates that each pending application is being reviewed within a different technical specialization at the USPTO.
The busiest examiner, HERNANDEZ, JACKSON J, is responsible for 1 pending office action. Because the 4 pending office actions are split among 4 distinct examiners, the workload is distributed across the portfolio without concentration. This arrangement requires the company to manage 4 separate examiner relationships simultaneously within the Biotechnology & Pharmaceuticals sector. The alignment of 4 distinct examiners with 4 distinct art units suggests that the company's current legal challenges are handled by multiple examination groups.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| STIGELL, THEODORE J | 1 | 78.3% | +14.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043868 | CHEWABLE FORMULATIONS | SONG, JIANFENG | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253061 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | LEE, CHIHYI NMN | 60d overdue |
| 18043868 | CHEWABLE FORMULATIONS | SONG, JIANFENG | 14d |
| 17795341 | WINGED CAPSULE | STIGELL, THEODORE J | 29d |
| 18255134 | BICYCLIC DERIVATIVES | HERNANDEZ, JACKSON J | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1628 | 1 |
| 1613 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18255134 | BICYCLIC DERIVATIVES | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | — | Pending | May 31, 2023 |
| 18253061 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | LEE, CHIHYI NMN | 1628 | §102§103§112DP | Final Rejection | 60d overdue | Pending | May 16, 2023 |
| 18043868 | CHEWABLE FORMULATIONS | SONG, JIANFENG | 1613 | §103§112 | Final Rejection | 14d | Pending | Mar 02, 2023 |
| 17795341 | WINGED CAPSULE | STIGELL, THEODORE J | 3783 | §103 | Final Rejection | 29d | Pending | Jul 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial